[Skip to Navigation]
Sign In

October 2021 - January 1920

Decade

Year

Issue

September 2021, Vol 157, No. 9, Pages 1027-1136

Viewpoint

Melanoma and Racial Health Disparities in Black Individuals—Facts, Fallacies, and Fixes

Abstract Full Text
JAMA Dermatol. 2021;157(9):1031-1032. doi:10.1001/jamadermatol.2021.2215

This Viewpoint examines survival rates of and risks of screening for melanoma in Black individuals.

Communication Between Dermatologists and Dermatopathologists via the Pathology Requisition: Opportunities to Improve Patient Care

Abstract Full Text
JAMA Dermatol. 2021;157(9):1033-1034. doi:10.1001/jamadermatol.2021.2582

This Viewpoint examines the importance of the working relationship between dermatologists and dermatopathologists.

Editorial

What Matters the Most to Adult Women With Acne?

Abstract Full Text
JAMA Dermatol. 2021;157(9):1035-1037. doi:10.1001/jamadermatol.2021.2184
Original Investigation

Patient Perspectives on the Lived Experience of Acne and Its Treatment Among Adult Women With Acne: A Qualitative Study

Abstract Full Text
has audio
JAMA Dermatol. 2021;157(9):1040-1046. doi:10.1001/jamadermatol.2021.2185

This qualitative study examines the lived experience of acne and its treatment among a cohort of 50 women.

Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial

Abstract Full Text
open access has active quiz
JAMA Dermatol. 2021;157(9):1047-1055. doi:10.1001/jamadermatol.2021.3023

This randomized clinical trial assesses the safety and efficacy of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis.

Association Between Biologics Use and Risk of Serious Infection in Patients With Psoriasis

Abstract Full Text
JAMA Dermatol. 2021;157(9):1056-1065. doi:10.1001/jamadermatol.2021.2599

This cohort study uses data from the French National Health Data System to assess the risk of serious infection among biologics and apremilast used to treat psoriasis, with etanercept as the comparator.

Evaluation of Long-term Clearance Rates of Interventions for Actinic Keratosis: A Systematic Review and Network Meta-analysis

Abstract Full Text
JAMA Dermatol. 2021;157(9):1066-1077. doi:10.1001/jamadermatol.2021.2779

This network meta-analysis evaluates the long-term outcomes of agents used in treatment of patients with actinic keratosis.

Assessment of Diagnostic Accuracy of Dermoscopic Structures and Patterns Used in Melanoma Detection: A Systematic Review and Meta-analysis

Abstract Full Text
JAMA Dermatol. 2021;157(9):1078-1088. doi:10.1001/jamadermatol.2021.2845

This systematic review and meta-analysis assesses the diagnostic accuracy of individual dermoscopic structures and patterns, as defined by standardized dermoscopy terminology, used in melanoma detection.

Validity of Using Billing Codes From Electronic Health Records to Estimate Skin Cancer Counts

Abstract Full Text
JAMA Dermatol. 2021;157(9):1089-1094. doi:10.1001/jamadermatol.2021.2856

This cohort study assesses whether standard diagnostic and procedural codes present in the electronic health records (EHRs) at a single health care system are a valid proxy for estimating the number of overall skin cancers.

Differences Between Children and Adults With Hidradenitis Suppurativa

Abstract Full Text
has audio
JAMA Dermatol. 2021;157(9):1095-1101. doi:10.1001/jamadermatol.2021.2865

This cohort study examines clinical characteristics and health care utilization patterns of pediatric vs adult patients with hidradenitis suppurativa.

Brief Report

Association of Second-Opinion Strategies in the Histopathologic Diagnosis of Cutaneous Melanocytic Lesions With Diagnostic Accuracy and Population-Level Costs

Abstract Full Text
JAMA Dermatol. 2021;157(9):1102-1106. doi:10.1001/jamadermatol.2021.1779

This decision-analytic model estimates the potential association of second-opinion strategies in the histopathologic diagnosis of cutaneous melanocytic lesions with diagnostic accuracy and 1-year population-level costs in the US.

Neonatal Linear IgA Bullous Dermatosis Mediated by Breast Milk–Borne Maternal IgA

Abstract Full Text
JAMA Dermatol. 2021;157(9):1107-1111. doi:10.1001/jamadermatol.2021.2392

This case report examines a case of linear immunoglobulin A bullous dermatosis in a breast-fed newborn with an asymptomatic mother.

JAMA Dermatology Clinical Evidence Synopsis

A Multidisciplinary Collaborative Approach to Retinal Toxic Effects Screening for Dermatology Patients Taking Antimalarials

Abstract Full Text
JAMA Dermatol. 2021;157(9):1112-1113. doi:10.1001/jamadermatol.2021.2699

This Clinical Evidence Synopsis summarizes a joint position statement on the roles of antimalarial therapy prescribers and eye care specialists in regard to dosing, screening for retinal toxic effects, and therapy cessation.

Images in Dermatology

Epidermolytic Hyperkeratosis

Abstract Full Text
JAMA Dermatol. 2021;157(9):1114. doi:10.1001/jamadermatol.2021.2325

This case report describes annular erythematous plaques and corrugated scaling of the flexures.

Tinea Facei From Trichophyton benhamiae From a Pet Guinea Pig

Abstract Full Text
JAMA Dermatol. 2021;157(9):1115. doi:10.1001/jamadermatol.2021.2566

This case report describes a scaly and crusted annular plaque with sharply demarcated edges on the central face with right eyebrow, right eyelid, and nasal involvement.

JAMA Dermatology Clinicopathological Challenge

Erythematoedematous and Sclerotic Plaques in a Man Receiving Systemic Chemotherapy

Abstract Full Text
has active quiz
JAMA Dermatol. 2021;157(9):1116-1117. doi:10.1001/jamadermatol.2021.2576

A man with stage IV adenocarcinoma of the lung receiving pemetrexed-pembrolizumab presented with redness and swelling of both lower limbs, and sclerotic changes were seen on the biopsy specimen. What is your diagnosis?

Bright Red Macules of the Lower Legs

Abstract Full Text
has active quiz
JAMA Dermatol. 2021;157(9):1118-1119. doi:10.1001/jamadermatol.2021.2980

A woman in her 70s with a diagnosis of peripheral neuropathy 6 years earlier presented with concerns for vasculitis of the bilateral lower legs and rapid progression of symptoms. What is your diagnosis?

JAMA Dermatology Patient Page

Vitiligo

Abstract Full Text
free access
JAMA Dermatol. 2021;157(9):1136. doi:10.1001/jamadermatol.2021.1688

This Patient Page describes the symptoms, possible causes, and treatment of vitiligo.

Research Letter

Association Between Gender-Affirming Hair Removal and Mental Health Outcomes

Abstract Full Text
JAMA Dermatol. 2021;157(9):1120-1122. doi:10.1001/jamadermatol.2021.2551

This secondary analysis uses data from the 2015 US Transgender Survey to assess the association between gender-affirming hair removal procedures and mental health among transgender individuals.

Clinical Settings and Demographic Characteristics of Patients With Sunburn

Abstract Full Text
JAMA Dermatol. 2021;157(9):1122-1125. doi:10.1001/jamadermatol.2021.2923

This cross-sectional study examines sunburn in claims data as well as the clinical settings and demographic characteristics of patients who receive sunburn diagnoses.

Racial and Ethnic Distribution of Patients Hospitalized With Hidradenitis Suppurativa, 2008-2018

Abstract Full Text
JAMA Dermatol. 2021;157(9):1125-1127. doi:10.1001/jamadermatol.2021.2999

This cohort study assesses hidradenitis suppurativa–related hospitalizations in the US from 2008 to 2018 to understand the racial breakdown among those with hidradenitis suppurativa.

Observation

Cytotoxic T-Lymphocyte Antigen–4 Haploinsufficiency Cutaneous Manifestations

Abstract Full Text
JAMA Dermatol. 2021;157(9):1127-1128. doi:10.1001/jamadermatol.2021.2317

This case report describes a female teenager with mild eczema and patchy alopecia areata presenting with a severe headache, gastrointestinal distress, fatigue, arthralgias, and skin eruption on bilateral extremities.

Association of Facial Pustular Neutrophilic Eruption With Messenger RNA–1273 SARS-CoV-2 Vaccine

Abstract Full Text
free access
JAMA Dermatol. 2021;157(9):1128-1130. doi:10.1001/jamadermatol.2021.2474

This case report describes 2 patients with facial eruption that developed within 24 hours of receiving a first dose of a messenger RNA SARS-CoV-2 vaccine.

JAMA Dermatology Masthead

JAMA Dermatology

Abstract Full Text
free access
JAMA Dermatol. 2021;157(9):1027. doi:10.1001/jamadermatol.2020.3902
×